JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. - Equity Right - Laporan Laba Rugi (TTM)

JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. - Equity Right
TH ˙ SET
Laporan Laba Rugi (TTM)

Laporan Laba Rugi JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. - Equity Right menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 463 433 421 422 429 419 419 419 467 506 518 585 594 628 703 769 846 918 984
Change (%) -6.44 -2.72 0.29 1.59 -2.40 -0.05 0.12 11.37 8.31 2.53 12.94 1.53 5.62 11.91 9.47 10.00 8.57 7.17
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 310 285 273 274 278 277 284 286 313 340 361 417 432 458 484 491 519 545 570
Change (%) -8.11 -4.19 0.48 1.37 -0.24 2.23 0.80 9.57 8.48 6.42 15.48 3.50 5.96 5.83 1.40 5.75 4.97 4.45
% of Revenue 67.00 65.80 64.80 64.92 64.78 66.21 67.72 68.18 67.08 67.18 69.74 71.31 72.69 72.93 68.96 63.88 61.41 59.37 57.87
Gross Operating Profit 153 148 148 148 151 142 135 133 154 166 157 168 162 170 218 278 326 373 415
Change (%) -3.05 0.12 -0.04 2.00 -6.37 -4.51 -1.31 15.23 7.95 -5.45 7.08 -3.37 4.71 28.30 27.40 17.51 14.30 11.14
% of Revenue 33.00 34.20 35.20 35.08 35.22 33.79 32.28 31.82 32.92 32.82 30.26 28.69 27.31 27.07 31.04 36.12 38.59 40.63 42.13
SG&A 100 98 95 96 103 118 135 149 155 154 152 155 163 170 180 197 224 257 282
Change (%) -1.70 -2.76 0.35 7.64 14.52 14.50 10.57 3.78 -0.65 -0.97 1.81 4.96 4.51 6.09 9.03 13.93 14.74 9.75
% of Revenue 21.53 22.62 22.61 22.62 23.97 28.12 32.22 35.58 33.15 30.41 29.38 26.48 27.38 27.09 25.68 25.58 26.49 28.00 28.67
R&D
Change (%)
% of Revenue
OpEx 410 383 368 370 381 395 418 435 468 493 514 572 595 628 665 688 744 802 852
Change (%) -6.55 -3.83 0.44 2.99 3.75 5.89 3.95 7.59 5.46 4.12 11.43 3.89 5.56 5.90 3.47 8.09 7.91 6.15
% of Revenue 88.52 88.42 87.41 87.54 88.75 94.33 99.93 103.76 100.23 97.60 99.11 97.79 100.07 100.02 94.64 89.45 87.90 87.37 86.54
Operating Income 53 50 53 53 48 24 0 -16 -1 12 5 13 -0 -0 38 81 102 116 133
Change (%) -5.58 5.75 -0.75 -8.24 -50.85 -98.83 -5,791.67 -93.18 -1,231.25 -62.21 181.79 -103.15 -75.23 -37,340.36 115.43 26.20 13.34 14.22
% of Revenue 11.48 11.58 12.59 12.46 11.25 5.67 0.07 -3.76 -0.23 2.40 0.89 2.21 -0.07 -0.02 5.36 10.55 12.10 12.63 13.46
Interest Expense -11 -11 -10 -11 -10 -10 -10 -9 -9 -10 -10 -12 -13 -15 -16 -17 -17 -16 -16
Change (%) -3.99 -5.44 1.35 -1.20 -6.41 4.78 -7.02 -3.11 7.80 2.54 13.73 12.50 12.62 8.34 5.01 -0.50 -0.79 -5.49
% of Revenue -2.47 -2.54 -2.47 -2.49 -2.42 -2.32 -2.44 -2.26 -1.97 -1.96 -1.96 -1.97 -2.19 -2.33 -2.26 -2.17 -1.96 -1.79 -1.58
Net Income 31 29 32 32 30 11 -13 -24 -17 -4 -6 2 -2 -6 22 51 5 14 28
Change (%) -5.87 8.84 0.64 -7.36 -64.19 -223.31 84.14 -27.58 -76.88 37.53 -144.80 -169.04 251.51 -455.85 137.92 -91.16 220.04 96.34
% of Revenue 6.72 6.76 7.56 7.59 6.92 2.54 -3.13 -5.76 -3.75 -0.80 -1.07 0.43 -0.29 -0.96 3.06 6.65 0.53 1.58 2.89

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista